Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase NA 20Phase 1 18Phase 3 14Phase 1/2 11Phase 4 1Phase 2/3 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 40Neoplasms 36Prostatic Neoplasms 32Colorectal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 14Polycystic Ovary Syndrome 13Lung Neoplasms 13Stomach Neoplasms 12Multiple Myeloma 11Carcinoma, Hepatocellular 11Recurrence 10Pancreatic Neoplasms 10Urinary Bladder Neoplasms 9Lymphoma 9Leukemia 9Myelodysplastic Syndromes 8Motor Activity 8Head and Neck Neoplasms 8Liver Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Esophageal Neoplasms 7Colonic Neoplasms 7Brain Neoplasms 7Pain 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Peritoneal Neoplasms × Clear all
NCT00443196 2018-03-12

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

Pierian Biosciences

Phase 2/3 Completed
150 enrolled
Gynecologic

Adenocarcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡